Search Results - pancreatic+cancer

7 Results Sort By:
Full Spectrum Computer Vision for Photon Counting CT (Case No. 2024-058)
Summary: Researchers in the Department of Radiological Sciences have developed a machine learning algorithm that processes multispectral photon counting CT data for accurate medical imaging. Background: Photon counting computed tomography (PCCT) is a tremendous engineering advancement, enabling high resolution spectral imaging with myriad applications....
Published: 9/20/2024   |   Inventor(s): Matthew Brown, Dieter Enzmann, John Hoffman, Michael Mcnitt-Gray
Keywords(s): AI algorithms, Algorithm, Algorithm Optical Coherence Tomography, algorithmic cancer detection, Artifical Intelligence (Machine Learning, Data Mining), artificial electromagnetic materials, Artificial Intelligence, artificial intelligence augmentation, Artificial Neural Network, Artificial Neural Network Artificial Neuron, artificial-intelligent materials, Big Data, Bladder Cancer, blood cancers, Brain cancer, Breast Cancer, Cancer, cancer antigen, cancer detection, Cancer Immunotherapy, Cancer stem cells, cancer target, Computed tomography, CT, Deep Learning, design software, Digital Pathology, generative artificial intelligence, Genetic Algorithm, Histopathological image analysis, Histopathology, histopathology images, hyperparameter optimization, Image Analysis, Image Processing, lympathic cancers, lymphatic cancer, Medical artificial intelligence (AI), Mesenchymal Stem Cell Derived Cancer Cells, Orthotopic cancer models, Pancreatic cancer, pathology image analysis, Photon counting computed tomography (PCCT), prostate cancer, Radiology, Radiology / Radiomitigation, Software, Software & Algorithms, Software Development Tools, Software-enabled learning
Category(s): Software & Algorithms, Software & Algorithms > Image Processing, Software & Algorithms > Artificial Intelligence & Machine Learning, Software & Algorithms > Data Analytics
CD206 Small Molecule Modulators, Their Use and Methods for Preparation
Abstract: Pancreatic ductal adenocarcinoma (PDA) accounts for more than 90% of pancreatic cancer cases, and it is one of the most aggressive malignancies with a 5-year survival rate of 6%. The high mortality rate caused by PDA is primarily from the lack of early diagnosis – it is often asymptomatic in early stages – and a poor response to conventional...
Published: 4/8/2024   |   Inventor(s): Udo Rudloff, Juan Marugan, Xin Hu, Raul Calvo, Noel Southall, Bolormaa Baljinnyam
Keywords(s): CD206, M1 Macrophage, M2 Macrophage, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDA, Rudloff, TAM, Tumor-Associated Macrophages
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration
Synthetic lipopeptide inhibitors of RAS oncoproteins
Abstract: It is well known that overactive Ras signaling is linked to many forms of cancer, and despite intensive efforts worldwide to develop effective inhibitors of Ras, to date there is no anti-Ras inhibitor in clinical use. Researchers at the NCI’s Cancer and Inflammation Program, in collaboration with scientists at Vanderbilt University and the...
Published: 6/11/2024   |   Inventor(s): Nadya Tarasova, Sergey Tarasov, Vadim Gaponenko, Joseph Kates, Michael Dean, Alla Ivanova
Keywords(s): COLON, LUNG, MULTIPLE MYELOMA, Pancreatic Cancer, RAS, THYROID CANCER
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors
Abstract: CD276 (also called B7-H3) is a pan-cancer antigen expressed in multiple solid tumors and an emerging cancer target. CD276 protein is overexpressed in pancreatic cancer, prostate cancer, breast cancer, colon cancer, lung cancer, and brain tumors (such as neuroblastoma) – making it an ideal target for cancer therapy.  Investigators at the National...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Brad St. Croix, Ruixue Wang, Dan Li
Keywords(s): ADC, Antibody-drug Conjugate, B7-H3, BREAST CANCER, CAR, CD276, chimeric antigen receptor, COLON CANCER, Glioma, HO, lung cancer, Nanobodies, Neuroblastoma, OVARIAN CANCER, Pancreatic Cancer, solid tumors
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology
IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors
Abstract: Pancreatic cancer is the fourth most common cause of cancer deaths in the U.S. The overall 5-year survival rate is 8.5%. Glypican-1 (GPC1) is a cell surface heparan sulfate proteoglycan protein overexpressed in pancreatic cancer. Due to preferential expression, GPC1 represents a potential candidate for targeted therapy for pancreatic cancer...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Jessica Hong
Keywords(s): cancer therapeutic, CAR, chimeric antigen receptor, Glypican-1, GPC-1, Hinge, HO, IgG4, Immunoglobulin subclass 4, NANOBODY, Pancreatic Cancer, Single Domain Antibody
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology
High Affinity Monoclonal Antibodies Targeting Glypican-1
Abstract: Pancreatic cancer is the fourth most common cause of death from cancer in the U.S. The overall 5-year survival rate for this disease is 8.5%. Glypican-1 (GPC1), a cell surface heparan sulfate proteoglycan protein that is overexpressed in pancreatic cancer. Due to this preferential expression, GPC1 represents a potential candidate for targeted...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Nan Li
Keywords(s): ADC, Antibody-drug Conjugate, Bispecific Antibody, CAR, chimeric antigen receptor, Glypican-1, GPC1, HO, Immunotoxin, NANOBODY, Pancreatic Cancer, Recombinant Immunotoxin, Rit, Single Domain Antibody
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Therapeutics
Syringe Stabilization Device for Ultrasound-Guided Procedures (UCLA Case No. 2023-045)
Summary: UCLA researchers in the Department of Surgery have developed a novel, minimally invasive ultra-sounded guided metastatic mouse model and device enabling more secure and precise usage of in-plane ultrasound imaging of needles. Background: Cancer is the second leading cause of death globally and in the United States. Pancreatic cancer remains...
Published: 11/8/2023   |   Inventor(s): Amanda Labora
Keywords(s): Breast Cancer, Cancer, cancer detection, Cancer Immunotherapy, Catheterization, In-plane ultrasound, Intratumoral drug delivery, Metastasis, metastatic mouse model, Mouse model, Orthotopic cancer models, Pancreatic cancer, Preclinical model development, Preclinical surgical innovation
Category(s): Life Science Research Tools, Life Science Research Tools > Animal Imaging, Life Science Research Tools > Animal Models, Medical Devices > Medical Imaging, Therapeutics, Therapeutics > Oncology, Medical Devices > Medical Imaging > Ultrasound